Furthermore, activation of antitumor immune response by cancer vaccines may not induce tumor regression, whereas tumors respond by upregulating immune checkpoint ligands inducing immunosuppression.9 Very encouraging results coming from early phase trials have been presented in patients treated with cancer vaccines combined with immune checkpoint inhibitors such as anti-PD19,20,32 and anti-CTLA4.17,18,33 In our study, each AGI-101H dose administration induced increase of the number of melanoma antigen-specific CD8+ cytotoxic lymphocytes (CTL) (data not published). Here, CTLA4 is linked to melanoma.